Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria

Organon and Co3,011 enrolled

Overview

Eligible patients will be prescribed Desloratadine 1 tablet of 5 mg once daily. Patients will be asked to follow-up for a final visit after 14 days (Day 15) where the safety, tolerability and clinical efficacy will be measured.

Study Type

OBSERVATIONAL

Enrollment

3,011

Conditions

Rhinitis Urticaria

Interventions

DesloratadineDRUG

Desloratadine 5 mg once daily

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Outpatient men or women, age 12 years and above. * Diagnosis of Allergic Rhinitis or Chronic Idiopathic Urticaria Exclusion Criteria: * Known hypersensitivity to Desloratadine. * Pregnancy or lactation

Outcomes

Primary Outcomes

Adverse Events

Number of adverse events reported

Time frame: Final Visit (Day 15)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.